Quest Diagnostics Incorporated (DGX)

NYSE: DGX · USD

$245

+2.86 (+1.2%)· Recorded snapshot

Engelse bronNL

Engelse bron wordt weergegeven terwijl we vertalen

Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.

StockMarketAgent Research · Analyzed 2026-05-13

Our latest published analysis: DGX rated Buy

Quest Diagnostics Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$226 / share

Potential value

$268 / share

Upside to FV

+18.9%

from $245

Moat

6.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$21.1B
Revenue (ttm)	11.8B
Net income (ttm)	1.1B
EPS (ttm)	$10.0
Shares out	110M
P/E (trailing)	24.5x
P/E (forward)	16.3x
Dividend	$3.44 (1.40%)
Volume	730,735
Beta	0.54

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11.8B
Net income (ttm): 1.1B
EPS (ttm): $10.0
P/E (trailing): 24.5x
P/E (forward): 16.3x
Market cap: $21.1B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$10.79B	$9.88B	$9.25B	$9.87B	$11.04B	+0.6%
Gross profit	$4.21B	$3.43B	$3.05B	$3.24B	$3.67B	-3.4%
Operating income	$2.75B	$1.38B	$1.29B	$1.40B	$1.60B	-12.7%
Net income	$2.00B	$946.0M	$854.0M	$871.0M	$992.0M	-16.0%
EPS (diluted)	$15.55	$7.97	$7.49	$7.69	$8.75	-13.4%
EBITDA	$3.16B	$1.82B	$1.73B	$1.89B	$2.17B	-9.0%
R&D	—	—	—	—	—	—
SG&A	$1.73B	$1.87B	$1.64B	$1.77B	$1.97B	+3.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Verkopen
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Verminderen
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	Aanhouden
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Verminderen
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	Sterk kopen
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	Kopen

Base and Bull scenarios

Bull20%

Price target

$267.84

+40.8% from spot

Accretive hospital lab system acquisitions, expansion in advanced and esoteric testing (e.g., Alzheimer's, cancer), and continued realization of cost synergies lead to margin expansion and faster-than-expected organic growth.

Operating margins expand beyond historical averages.
Rapid accretion from esoteric testing lines.
Successful integration of bolt-on acquisitions.

Base60%

Price target

$226.02

+18.8% from spot

Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend.

Year 1 revenue growth of 7.42%.
Terminal growth rate of 2.5%.
WACC stabilized at 6.27%.

Sensitivity: Ke × terminal growth

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
4.3%	$308	$375	$396	$396	$396
5.3%	$226	$261	$308	$375	$396
6.3%	$179	$200	$226	$261	$308
7.3%	$148	$162	$179	$200	$226
8.3%	$126	$136	$148	$162	$179

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E16.3

P25 n/aP50 n/aP75 n/a

Trailing P/E21

P25 n/aP50 n/aP75 n/a

ROE15.3

P25 n/aP50 n/aP75 n/a

ROIC10

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DGX indicators

Market & fundamental data

Available fields

288

Groups with data

Currency

USD

Showing 288 of 288 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001022079
Company name	Quest Diagnostics Incorporated
Country	United States
Country code	US
CUSIP number	74834L100
Earnings date	2026-10-22
Earnings time	bmo
Employees	57,000
Employees change	1,000
Employees growth	1.79%
Enterprise value	$32.6B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1967
In index	SP500
Industry	Diagnostics & Research
IPO date	1996-12-17
Is primary listing	Yes
Is SPAC	No
ISIN number	US74834L1008
Last 10-K release date	2026-02-26
Last earnings date	2026-10-22
Last refreshed	2026-10-28
Last stock split date	2005-06-21
Last stock split type	Forward
Market cap	$27B
Market cap category	Large-Cap
Next earnings date	2027-02-09
Options	Yes
Price	$245.42
Price currency	USD
Sector	Healthcare
SIC code	8071
Stock price date	2026-10-28
Symbol	DGX
U.S. state	New Jersey
Website	https://www.questdiagnostics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	22.23x
Average P/E ratio (10Y)	17.11x
Average P/E ratio (3Y)	20.34x
Average P/E ratio (5Y)	18.12x
Earnings yield	4.09%
EV/Earnings	29.06x
EV/EBIT	18.5x
EV/EBITDA	13.9x
EV/FCF	23.77x
EV/Sales	2.76x
FCF / EV yield	4.21%
FCF yield	5.08%
Forward EV/Sales	2.61x
Forward P/E	21.23x
Forward P/S	2.17x
Graham number	125.17493
Graham upside	-49.16%
Industry forward P/E	30.92x
Industry P/E	50.57x
Lynch fair value	$50.19
Lynch upside	-79.62%
P/(FCF - SBC) ratio	21.05x
P/(OCF - SBC) ratio	14.54x
P/B ratio	3.5x
P/E ratio	24.45x
P/FCF ratio	19.7x
P/OCF ratio	13.88x
P/S ratio	2.29x
PEG ratio	2.23x
Price/EBITDA ratio	11.52x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	14.92%
EBITDA margin	19.86%
Effective tax rate	22.47%
FCF margin	11.61%
Gross margin	33.18%
Operating margin	14.92%
Pretax margin	12.85%
Profit margin	9.53%
Profit per employee	$19,737
Profitable quarters	62
Profitable years	26
Revenue per employee	$207,737
ROA	6.61%
ROA (5Y)	7.22%
ROCE	11.48%
ROE	15.32%
ROE (5Y)	18.06%
ROIC	10.03%
ROIC (5Y)	11.34%
SBC / revenue	0.74%
Tax / revenue	2.89%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	17.89%
EPS growth (Q)	28.7%
EPS growth (QoQ)	-2.11%
EPS growth 10Y	7.86%
EPS growth 3Y	14.62%
EPS growth 5Y	-9.61%
EPS growth quarters	9
EPS growth years	2
FCF growth	-1.29%
FCF growth (Q)	6.21%
FCF growth (QoQ)	-3.05%
FCF growth 3Y	32.14%
FCF growth 5Y	-5.98%
Gross profit growth	8.21%
Gross profit growth (Q)	9.57%
Gross profit growth 3Y	8.17%
Gross profit growth 5Y	-2.71%
Net income growth	16.51%
Net income growth (Q)	27.35%
Net income growth (QoQ)	-2.82%
Net income growth 3Y	14.02%
Net income growth 5Y	-12.35%
Net income growth quarters	9
Net income growth years	2
OCF growth	3.5%
OCF growth (Q)	8.53%
OCF growth (QoQ)	2.35%
OCF growth 10Y	6.52%
OCF growth 3Y	21.83%
OCF growth 5Y	-3.18%
Operating income growth	12.84%
Operating income growth (Q)	16.91%
Operating income growth 3Y	12.05%
Operating income growth 5Y	-8.36%
Revenue growth	9.13%
Revenue growth (Q)	9.98%
Revenue growth (QoQ)	1.77%
Revenue growth 10Y	4.67%
Revenue growth 3Y	8.4%
Revenue growth 5Y	1.4%
Revenue growth quarters	11
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-576M
Depreciation and amortization	$585M
EBIT	$1.8B
EBITDA	$2.4B
EPS	$10.04
FCF per share	$12.50
Financing cash flow	$-939M
Free cash flow	$1.4B
Free cash flow minus SBC	$1.3B
Gross profit	$3.9B
Income taxes	$342M
Investing cash flow	$-646M
Net borrowing	$-11M
Net cash flow	$365M
Net income	$1.1B
Operating cash flow minus SBC	$1.9B
Operating income	$1.8B
Revenue	$11.8B
Stock-based compensation	$88M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.43
Book value per share	$69.38
Debt / EBITDA	2.23
Debt / equity	0.8
Debt / FCF	4.65
Goodwill	$9.1B
Interest coverage	6.62
Long-term assets	$14.1B
Long-term liabilities	$7.4B
Net cash (debt)	$-5.6B
Net cash / market cap	-20.67%
Net debt / EBITDA	2.38
Net debt / equity	0.7
Net debt / FCF	4.07
Piotroski F-Score	6
Property, plant and equipment	$2.9B
Shareholders' equity	$8B
Tangible book value	$-3.1B
Tangible book value per share	$-28.31
Total assets	$17.2B
Total cash	$797M
Total debt	$6.4B
Total liabilities	$9.2B
WACC	6.46%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.71
Current assets	$3.1B
Current liabilities	$1.8B
Current ratio	1.7
Inventory turnover	39.17
Net working capital	$677M
Quick ratio	1.37
Working capital	$1.3B
Working capital turnover	15.22

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.32%
Dividend growth	7.3%
Dividend growth (10Y)	7.9%
Dividend growth (3Y)	6.6%
Dividend growth (5Y)	6.91%
Dividend growth years	14
Dividend payment date	2026-10-21
Dividend payment years	23
Dividend payout frequency	Quarterly
Dividend per share	$3.44
Dividend yield	1.4%
Ex-dividend date	2026-10-06
FCF payout ratio	27.52%
Last dividend	$0.86
Payout ratio	34.27%
Shareholder yield	2.72%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	207.04%
10Y return CAGR	14.1%
10Y total return	273.76%
150-day SMA	$216.40
15Y price change	331.08%
15Y return CAGR	12.4%
15Y total return	477.56%
1D price change	1.18%
1M price change	3.85%
1M total return	4.24%
1W price change	2.71%
1W total return	2.71%
1Y price change	36.15%
1Y return CAGR	38.47%
1Y total return	38.44%
20-day SMA	$235.58
200-day SMA	$211.46
20Y price change	393.79%
20Y return CAGR	10.12%
20Y total return	587.42%
3M price change	5.86%
3M total return	6.25%
3Y price change	92.21%
3Y return CAGR	26.7%
3Y total return	103.42%
50-day SMA	$238.10
50-day SMA vs 200-day SMA	50over200
52-week high	$249.73
52-week high date	2026-10-28
52-week low	$171.18
52-week low date	2026-01-05
5Y price change	70.5%
5Y return CAGR	13.43%
5Y total return	87.78%
6M price change	24.81%
6M total return	25.78%
All-time high	$249.73
All-time high date	2026-10-28
All-time low	$3.31
All-time low date	1996-12-18
Average true range (ATR)	$6.28
Average volume	1M
Beta (1Y)	-0.46
Beta (2Y)	0
Beta (5Y)	0.54
Change from 52-week high	-1.73%
Change from 52-week low	43.37%
Change from all-time high	-1.73%
Change from all-time low	7,307.64%
Change from open	0.64%
Day's gap	0.53%
Dollar volume	$179.3M
High price	$249.57
Low price	$243.85
Monthly RSI	69.4
Open price	$243.85
Position in 52-week range	27.36%
Previous close	$242.56
Price vs 150-day SMA	13.41%
Price vs 20-day SMA	4.17%
Price vs 200-day SMA	16.06%
Price vs 50-day SMA	3.07%
Relative volume	0.71
RSI	63.11
Sharpe ratio	1.32
Sharpe ratio (3Y)	1.06
Sharpe ratio (5Y)	0.48
Sortino ratio	2.67
Sortino ratio (3Y)	2.07
Sortino ratio (5Y)	1
Volume	730.7K
Weekly RSI	65.63
YTD price change	41.43%
YTD total return	43.8%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	109.5M
Float percentage	99.49%
Shares change (QoQ)	0%
Shares change (YoY)	-1.32%
Shares held by insiders	0.36%
Shares held by institutions	97.25%
Shares outstanding	110M
Short % of float	3.12%
Short % of shares	3.11%
Short ratio	3 days

Deeper analysis on DGX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this DGX report

What is the latest published DGX stock rating?

Quest Diagnostics Incorporated is shown with Buy in the latest published report, analyzed 2026-05-13. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DGX analysis?

The full latest published report, analyzed 2026-05-13, lives at /stocks/DGX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for DGX?

The latest published report analyzed 2026-05-13 gives DGX a fair value of USD 226 and a potential value of USD 268. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the DGX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-13). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuyDGX · Fair value $226+18.9%

Read full analysis →

Quest Diagnostics Incorporated (DGX)

Our latest published analysis: DGX rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · DGX

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All DGX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DGX

Frequently asked questions

Ratinggeschiedenis

Category	Score	Reading
Valuation	7.5
Management	6.9
Balance Sheet	5.0
Profitability	5.0
Revenue Growth	6.0
Risk Assessment	7.5
Competitive Moat	6.5
Earnings Quality	8.0
Capital Efficiency	5.5